My watch list
my.bionity.com  
Login  

Oncology Alliance: Apeiron, CCRI and SIOPEN join forces against neuroblastoma

27-Jun-2011

Apeiron Biologics AG (Apeiron) announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

Dr. Hans Loibner, CEO of Apeiron, commented on the successful completion of the agreement: "This novel form of collaboration with CCRI and SIOPEN is a milestone for Apeiron. These non-profit organizations have accomplished remarkable clinical development achievements which we can now complement with our industrial know-how. With this collaboration, we add a project to our portfolio that is both innovative and close to the market."

Professor Ruth Ladenstein, head of the coordination center for clinical studies at CCRI, senior physician at St. Anna Kinderspital and European president of SIOP said: "We are convinced to have found an ideal partner in Apeiron for our project. Together, we will take the final steps of development for an urgently needed therapy against high-risk neuroblastoma. By applying immune therapy and other treatment improvements, we hope to increase the chances of survival for children with high-risk neuroblastoma by 30%, thereby rendering future survival rates of 60-70% realistic."

Financial details were not disclosed.

Facts, background information, dossiers
More about St. Anna Kinderkrebsforschung
  • Research Institutes

    St. Anna Kinderkrebsforschung

    The CCRI (Children's Cancer Research Institute) started its activities in 1988 under the leadership of Professor Helmut Gadner. In the last 23 years, the CCRI has accomplished pioneering work in many areas to improve the treatment quality and the chances for cure of children and adolescents ... more

More about SIOPEN
More about Apeiron Biologics
  • News

    APEIRON: New CEO announced

    APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO ... more

    Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

    Evotec AG and APEIRON Biologics AG announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of EUR 3 m will be split equally between the two biotech companies. The success payment was triggered when t ... more

    Evotec, Apeiron Biologics and Sanofi develop novel cancer immunotherapies

    Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematop ... more

  • Companies

    APEIRON Biologics AG

    Apeiron Biologics is engaged in the focused development of innovative therapeutics based on validated targets derived from biomedical break-through discoveries. The company, operational since 2005, was founded by Josef Penninger, a top level scientist with high international reputation and ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE